IRIS
FORMICA, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.987
EU - Europa 1.475
AS - Asia 848
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
AF - Africa 2
SA - Sud America 1
Totale 21.326
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.983
SG - Singapore 488
IT - Italia 255
UA - Ucraina 235
IE - Irlanda 229
CN - Cina 219
DE - Germania 187
RU - Federazione Russa 176
SE - Svezia 74
GB - Regno Unito 72
FR - Francia 70
PL - Polonia 65
KR - Corea 64
FI - Finlandia 61
ID - Indonesia 25
BE - Belgio 17
NL - Olanda 12
EU - Europa 8
JP - Giappone 7
CZ - Repubblica Ceca 6
HK - Hong Kong 6
IN - India 6
ES - Italia 5
AU - Australia 4
CA - Canada 4
KG - Kirghizistan 4
PH - Filippine 4
VN - Vietnam 4
CH - Svizzera 3
SA - Arabia Saudita 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
BD - Bangladesh 2
KW - Kuwait 2
MN - Mongolia 2
NO - Norvegia 2
TR - Turchia 2
TW - Taiwan 2
BG - Bulgaria 1
CL - Cile 1
EG - Egitto 1
IL - Israele 1
JO - Giordania 1
LT - Lituania 1
LU - Lussemburgo 1
MY - Malesia 1
NZ - Nuova Zelanda 1
RO - Romania 1
SC - Seychelles 1
Totale 21.326
Salva come PNG Salva come JPEG
Città #
Woodbridge 5.362
Wilmington 4.901
Houston 4.797
Fairfield 604
Singapore 435
Chandler 377
Ann Arbor 362
Ashburn 283
Seattle 267
Cambridge 222
Jacksonville 214
Dublin 210
Medford 165
Rome 116
New York 104
Santa Clara 104
Beijing 98
Dearborn 98
Engelhard 85
Lawrence 74
Menlo Park 73
Kraków 64
San Diego 50
Saint Petersburg 35
Moscow 33
Zhengzhou 32
Falls Church 24
Jakarta 24
Milan 24
Mülheim 19
Brussels 17
Boardman 16
London 14
Cagliari 10
Norwalk 10
Council Bluffs 9
Detroit 9
Hefei 9
Nanjing 9
Redwood City 9
Seoul 9
Hangzhou 8
Kunming 8
Palo Alto 8
Helsinki 7
Lappeenranta 7
Bologna 6
Creede 6
Del Norte 6
Los Angeles 6
Phoenix 6
Shanghai 6
University Park 6
Verona 6
Guangzhou 5
San Mateo 5
Turin 5
Amsterdam 4
Austin 4
Brno 4
Columbus 4
Fort Worth 4
Fremont 4
Monte Vista 4
Mountain View 4
Nepi 4
Nürnberg 4
Toronto 4
Anzio 3
Bangkok 3
Cedarhurst 3
Chengdu 3
Chongqing 3
Dong Ket 3
Fonte Nuova 3
Hong Kong 3
Jinan 3
Lishui 3
Manila 3
Munich 3
Nuremberg 3
Paris 3
Redmond 3
San Francisco 3
San Jose 3
Southwark 3
Tokyo 3
Treviso 3
Wuhan 3
Brescia 2
Bristol 2
Busto Arsizio 2
Central District 2
Changsha 2
Chaoyang 2
Chicago 2
Chiswick 2
Colorado Springs 2
Indiana 2
Kuwait City 2
Totale 19.607
Salva come PNG Salva come JPEG
Nome #
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report 468
Preclinical studies on detection of circulating melanoma cells in patients: Telomerase as a recognition marker of malignancy 445
Drug-induced increase of carcinoembryonic antigen expression in cancer cells 439
Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients 436
Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients 434
Impact of endoscopic ultrasound-guided fine-needle aspiration and multidisciplinary approach in the management of abdominal or mediastinal mass 433
Effects of conventional therapeutic interventions on the number and function of regulatory T cells 422
Immune reaction and colorectal cancer: friends or foes? 420
Biological and predictive role of ERCC1 polymorphisms in cancer 420
TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy 416
Prognostic value of glycated hemoglobin in colorectal cancer 414
Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio 413
Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer 412
Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells 412
Gender differences in cancer-associated venous thromboembolism 412
Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies 411
Thromboembolic events in patients treated with anti-angiogenic drugs 399
Rehabilitation in neuro-oncology: a meta-analysis of published data and a mono-institutional experience 399
Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression 395
Family history of cancer in patients with gastric cancer 392
VEGF gene promoter polymorphisms and risk of VTE in chemotherapytreated cancer patients 384
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer 380
Ensuring Sample Quality for Biomarker Discovery Studies - Use of ICT Tools to Trace Biosample Life-cycle 380
Are there alternative ways to quantify the real benefit of novel agents in oncology? - The 'death pace' 380
Insulinemia and the risk of breast cancer and its relapse 376
The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience 369
The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy 365
Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin 364
Up-regulation of carcinoembryonic antigen (CEA) expression by staurosporine in circulating colon cancer cells 363
Kallikrein-related peptidases targeted therapies in prostate cancer: Perspectives and challenges 360
Targeted therapy in first line treatment of RAS wild type colorectal cancer 360
CD26: a multi-purpose pharmacological target 359
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients 354
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro 347
VEGF gene polymorphisms may be associated with an increased risk of fluorouracil-induced diarrhea 346
Prognostic significance of serum adipokine levels in colorectal cancer patients 345
Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches 340
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B) 338
Non-steroidal anti-inflammatory drugs in cancer prevention and therapy 336
Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells 334
Caregiver distress in the early phases of cancer 330
A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes 327
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab 323
Percutaneous combined therapy for painful sternal metastases: a radiofrequency thermal ablation (RFTA) and cementoplasty protocol 318
Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome 309
Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer 292
Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt 292
Clinical significance of glycemic parameters on venous thromboembolism risk preDiction in gastrointestinal cancer 288
Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy 287
A novel K-ras mutation in colorectal cancer. A case report and literature review 286
Chemotherapy in patients with hereditary angioedema 272
Case report of a patient with breast metastasis from gastric cancer treated with paclitaxel and ramucirumab plus regional hyperthermia 271
Cancer patients in the emergency department: A "nightmare" that might become a virtuous clinical pathway 231
Histotype influences emergency presentation and prognosis in colon cancer surgery 195
Relevance of computed tomography and magnetic resonance imaging for penile metastasis after prostatectomy: uncommon case report and brief review of the literature 176
Complete blood count might help to identify subjects with high probability of testing positive to SARS-CoV-2 145
Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors 129
A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel 126
Clinical care pathway program versus open-access system: a study on appropriateness, quality, and efficiency in the delivery of colonoscopy in the colorectal cancer 83
Irinotecan or oxaliplatin: which is the first move for the mate? 82
Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt 75
Lymph node-only metastatic gastric/gastroesophageal junction cancer and efficacy of immunotherapy 74
Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care 72
Clinical utility of plasma KRAS, NRAS and BRAF mutational analysis with real time PCR in metastatic colorectal cancer patients -The importance of tissue/plasma discordant cases 70
Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice? 68
Clinical care pathway program versus open-access system: a study on appropriateness, quality, and efficiency in the delivery of colonoscopy in the colorectal cancer 66
The effects of association of topical polydatin improves the preemptive systemic treatment on EGFR inhibitors cutaneous adverse reactions 59
Endoscopic Ultrasound Plus Endoscopic Retrograde Cholangiopancreatography Based Tissue Sampling for Diagnosis of Proximal and Distal Biliary Stenosis Due to Cholangiocarcinoma: Results from a Retrospective Single-Center Study 46
Concordance of blood-based and normal tissue-based dihydropyrimidine dehydrogenase (DPYD) genotyping 41
Health-related quality of life in patients with advanced colorectal cancer: a predictive nomogram including BMI, sex and age 40
Solitary metachronous gastric metastasis from pulmonary adenocarcinoma: Report of a case 39
KRAS and BRAF Mutations in Stage II/III Colon Cancer: A Systematic Review and Meta-Analysis 39
Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview 37
Mucinous and Signet-Ring Cell Colonic Adenocarcinoma in Inflammatory Bowel Disease: A Case-Control Study 36
HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling 35
Issues and promises of bevacizumab in prostate cancer treatment 34
Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation 34
Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy? 31
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis 31
MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review 30
Role of systemic inflammation and CD45RO+CD8+c cells in metastatic colorectal cancer 28
A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma 28
Untailored vs. Gender- and Body-Mass-Index-Tailored Skeletal Muscle Mass Index (SMI) to Assess Sarcopenia in Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) 27
Hepcidin Upregulation in Colorectal Cancer Associates with Accumulation of Regulatory Macrophages and Epithelial–Mesenchymal Transition and Correlates with Progression of the Disease 26
Gender differences in cancer-associated venous thromboembolism 26
Role of systemic inflammation and CD45RO+CD8+ cells in metastatic colorectal cancer: ruolo dell’infiammazione e delle cellule CD45RO+CD8+ nei tumori colorettali metastatici 25
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram 24
Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer 24
Adjuvant therapy for very young women with breast cancer: Response according to biologic and endocrine features 24
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ?BRAF BeCool? study 23
Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors 20
Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer 19
Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events? 15
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the ?CARACAS? study 10
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response 7
PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials 4
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors 1
Totale 21.622
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.937
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.937
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.134 0 0 0 0 0 558 466 453 484 436 329 408
2020/20213.501 354 401 313 407 417 434 478 361 79 90 117 50
2021/2022895 35 85 38 50 44 70 88 68 74 89 50 204
2022/2023998 92 80 26 124 121 237 76 63 89 13 42 35
2023/2024588 43 16 36 23 33 109 177 55 8 5 5 78
2024/20251.031 58 510 218 132 35 78 0 0 0 0 0 0
Totale 21.622